trial

Sulforaphane to Reduce Symptoms of Schizophrenia

NCTId NCT02810964
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 64 (actual)
Sponsored by Sheppard Pratt Health System
Primary completion 2019-11-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
64 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2017-02-22
Primary completion
2019-11-11
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Sulforaphane Nutraceutical

Sponsors

Sheppard Pratt Health SystemLead Sponsor

Investigators

1
Faith B Dickerson, PhD, MPHPrincipal Investigator

Sites

1 total
Towson, United States

Linked catalysts

1
Sulforaphane to Reduce Symptoms of Schizophrenia — primary completion2019-11-11

Facts & assertions

4 sourced
Enrollment
64
Phase
PHASE2
Primary Completion Date
2019-11-11
Status
COMPLETED
relationships
The graph out of here
drug
Sulforaphane Nutraceutical
drug
lead_sponsor
Sheppard Pratt Health System
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Faith B Dickerson, PhD, MPH
person